CoChat

Therapeutic Potentials of Ketamine and Esketamine in Obsessive–Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature

Open access
Martinotti, Giovanni, Chiappini, Stefania, Pettorruso, Mauro, Mosca, Alessio, Miuli, Andrea, Di Carlo, Francesco, D’Andrea, Giacomo, Collevecchio, Roberta, Di Muzio, Ilenia, Sensi, Stefano L., Di Giannantonio, Massimo · 2021 · Brain Sciences
Cited by 111

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

The obsessive–compulsive spectrum refers to disorders drawn from several diagnostic categories that share core features related to obsessive–compulsive disorder (OCD), such as obsessive thoughts, compulsive behaviors and anxiety. Disorders that include these features can be grouped according to the focus of the symptoms, e.g., bodily preoccupation (i.e., eating disorders, ED) or impulse control (i.e., substance use disorders, SUD), and they exhibit intriguing similarities in phenomenology, etiology, pathophysiology, patient characteristics and clinical outcomes. The non-competitive N-methyl-D-aspartate receptor (NMDAr) antagonist ketamine has been indicated to produce remarkable results in patients with treatment-resistant depression, post-traumatic stress disorder and OCD in dozens of small studies accrued over the past decade, and it appears to be promising in the treatment of SUD and ED. However, despite many small studies, solid evidence for the benefits of its use in the treatment of OCD spectrum and addiction is still lacking. Thus, the aim of this perspective article is to examine the potential for ketamine and esketamine in treating OCD, ED and SUD, which all involve recurring and intrusive thoughts and generate associated compulsive behavior. A comprehensive and updated overview of the literature regarding the pharmacological mechanisms of action of both ketamine and esketamine, as well as their therapeutic advantages over current treatments, are provided in this paper. An electronic search was performed, including all papers published up to April 2021, using the following keywords (“ketamine” or “esketamine”) AND (“obsessive” OR “compulsive” OR “OCD” OR “SUD” OR “substance use disorder” OR “addiction” OR “craving” OR “eating” OR “anorexia”) NOT review NOT animal NOT “in vitro”, on the PubMed, Cochrane Library and Web of Science online databases. The review was conducted in accordance with preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. The use and efficacy of ketamine in SUD, ED and OCD is supported by glutamatergic neurotransmission dysregulation, which plays an important role in these conditions. Ketamine’s use is increasing, and preliminary data are optimistic. Further studies are needed in order to better clarify the many unknowns related to the use of both ketamine and esketamine in SUD, ED and OCD, and to understand their long-term effectiveness.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/brainsci11070856

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Research works printed but not linked: 63

  1. Nasir, 2020, Glutamate Systems in DSM-5 Anxiety Disorders: Their Role and a Review of Glutamate and GABA Psychopharmacology, Front. Psychiatry, 11, 548505, 10.3389/fpsyt.2020.548505 · DOI
  2. Hollander, 1995, Obsessive-compulsive spectrum disorders, J. Clin. Psychiatry, 56, 7
  3. Pittenger, 2015, Glutamatergic agents for OCD and related disorders, Curr. Treat. Options Psychiatry, 2, 271, 10.1007/s40501-015-0051-8 · DOI · Paper page
  4. Karthik, 2020, Investigating the Role of Glutamate in Obsessive-Compulsive Disorder: Current Perspectives, Neuropsychiatr. Dis. Treat., 16, 1003, 10.2147/NDT.S211703 · DOI
  5. Bartoli, 2017, Ketamine as a rapid-acting agent for suicidal ideation: A meta-analysis, Neurosci. Biobehav. Rev., 77, 232, 10.1016/j.neubiorev.2017.03.010 · DOI
  6. Strasburger, 2017, What is the mechanism of Ketamine’s rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities, J. Clin. Pharm. Ther., 42, 147, 10.1111/jcpt.12497 · DOI · Paper page
  7. Veraart, 2021, Oral S-ketamine effective after deep brain stimulation in severe treatment-resistant depression and extensive comorbidities, BMJ Case Rep., 14, e238135, 10.1136/bcr-2020-238135 · DOI
  8. Kohtala, S. (2021). Ketamine-50 years in use: From anesthesia to rapid antidepressant effects and neurobiological mechanisms. Pharmacol. Rep. · DOI · Paper page
  9. Peyrovian, 2020, Registered clinical trials investigating ketamine for psychiatric disorders, J. Psychiatr. Res., 127, 1, 10.1016/j.jpsychires.2020.03.020 · DOI · Paper page
  10. Cui, 2019, Crosstalk Between Inflammation and Glutamate System in Depression: Signaling Pathway and Molecular Biomarkers for Ketamine’s Antidepressant Effect, Mol. Neurobiol., 56, 3484, 10.1007/s12035-018-1306-3 · DOI
  11. Sleigh, 2014, Ketamine—More mechanisms of action than just NMDA blockade, Trends Anaesth. Crit. Care, 4, 76, 10.1016/j.tacc.2014.03.002 · DOI · Paper page
  12. Ricci, 2011, Chronic ketamine use increases serum levels of brain-derived neurotrophic factor, Psychopharmacology, 215, 143, 10.1007/s00213-010-2121-3 · DOI
  13. Gautam, 2020, Repurposing Potential of Ketamine: Opportunities and Challenges, Indian J. Psychol. Med., 42, 22, 10.4103/IJPSYM.IJPSYM_228_19 · DOI
  14. Musazzi, 2013, The action of antidepressants on the glutamate system: Regulation of glutamate release and glutamate receptors, Biol. Psychiatry, 73, 1180, 10.1016/j.biopsych.2012.11.009 · DOI · Paper page
  15. Douglas, 2007, Mapping the matrix: The ways of neocortex, Neuron, 56, 226, 10.1016/j.neuron.2007.10.017 · DOI · Paper page
  16. Sorice, 2019, Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD), Curr. Neuropharmacol., 17, 710, 10.2174/1570159X16666180813155017 · DOI · Paper page
  17. Stahl, S.M. (2017). Prescriber’s Guide: Stahl’s Essential Psychopharmacology, Cambridge University Press. [6th ed.].
  18. Kleber, H.D., Weiss, R.D., George, T.P., Anton, R., Greenfield, S.F., Kosten, T.R., O’Brien, C.P., Rounsaville, B.J., Strain, E.C., and Ziedonis, D.M. (2021, March 14). Treatment of Patients with Substance Use Disorders Second Edition-Work Group on Substance Use Disorders. Available online: https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/substanceuse.pdf.
  19. Allen, 2003, Obsessive-Compulsive spectrum disorders, Dialogues Clin. Neurosci., 5, 259, 10.31887/dcns.2003.5.3/aallen · DOI · Paper page
  20. Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement, PLoS Med., 6, e1000097, 10.1371/journal.pmed.1000097 · DOI · Paper page
  21. Adams, 2017, Intranasal Ketamine and Cognitive-Behavioral Therapy for Treatment-Refractory Obsessive-Compulsive Disorder, J. Clin. Psychopharmacol., 37, 269, 10.1097/JCP.0000000000000659 · DOI
  22. Lalanne, L., Nicot, C., Lang, J., Bertschy, G., and Salvat, E. (2016). Experience of the use of Ketamine to manage opioid withdrawal in an addicted woman: A case report. BMC Psychiatry, 16. · DOI
  23. Mills, 1998, Treatment of compulsive behaviour in eating disorders with intermittent ketamine infusions, QJM, 91, 493, 10.1093/qjmed/91.7.493 · DOI · Paper page
  24. Ocker, 2020, Ketamine and Cognitive Behavioral Therapy for Rapid Opioid Tapering With Sustained Opioid Abstinence: A Case Report and 1-Year Follow-up, Pain Pract., 20, 95, 10.1111/papr.12829 · DOI
  25. Omoigui, 2011, Use of Ketamine in Ameliorating Opioid Withdrawal Symptoms During an Induction Phase of Buprenorphine, Open Pain J., 4, 1, 10.2174/1876386301104010001 · DOI
  26. Schwartz, T., Trunko, M.L., Feifel, D., Lopez, E., Peterson, D., Frank, G.K.W., and Kaye, W. (2021). A longitudinal case series of IM ketamine for patients with severe and enduring eating disorders and comorbid treatment-resistant depression. Clin. Case Rep., 1–7. · DOI · Paper page
  27. Scolnick, 2020, Remission from Chronic Anorexia Nervosa with Ketogenic Diet and Ketamine: Case Report, Front. Psychiatry, 11, 763, 10.3389/fpsyt.2020.00763 · DOI · Paper page
  28. Dakwar, 2017, Cocaine self-administration disrupted by the N-methyl-D-aspartate receptor antagonist ketamine: A randomized, crossover trial, Mol. Psychiatry, 22, 76, 10.1038/mp.2016.39 · DOI · Paper page
  29. Bloch, 2012, Effects of ketamine in treatment-refractory obsessive-compulsive disorder, Biol. Psychiatry, 72, 964, 10.1016/j.biopsych.2012.05.028 · DOI · Paper page
  30. Niciu, 2013, Two cases of delayed-onset suicidal ideation, dysphoria and anxiety after ketamine infusion in patients with obsessive-compulsive disorder and a history of major depressive disorder, J. Psychopharmacol., 27, 651, 10.1177/0269881113486718 · DOI · Paper page
  31. Jovaisa, 2006, Effects of ketamine on precipitated opiate withdrawal, Medicina, 42, 625
  32. Krupitsky, 2007, Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence, J. Psychoact. Drugs, 39, 13, 10.1080/02791072.2007.10399860 · DOI · Paper page
  33. Pradhan, 2020, Combining Ketamine, Brain Stimulation (rTMS) and Mindfulness Therapy (TIMBER) for Opioid Addiction, Cureus, 12, e11798
  34. Rodriguez, 2016, Can Exposure-Based CBT Extend IV Ketamine’s Effects in Obsessive-Compulsive Disorder? An Open-Label Trial, J. Clin. Psychiatry, 77, 408, 10.4088/JCP.15l10138 · DOI · Paper page
  35. Rodriguez, 2017, Challenges in Testing Intranasal Ketamine in Obsessive-Compulsive Disorder, J. Clin. Psychiatry, 78, 466, 10.4088/JCP.16cr11234 · DOI
  36. Rodriguez, 2015, In vivo effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder: Proof of concept, Psychiatry Res., 233, 141, 10.1016/j.pscychresns.2015.06.001 · DOI · Paper page
  37. Rodriguez, 2016, Open-Label trial on the effects of memantine in adults with obsessive-compulsive disorder after a single ketamine infusion, J. Clin. Psychiatry, 77, 688, 10.4088/JCP.15l10318 · DOI · Paper page
  38. Wong, 2015, Evaluation of adjunctive ketamine to benzodiazepines for management of alcohol withdrawal syndrome, Ann. Pharmacother., 49, 14, 10.1177/1060028014555859 · DOI · Paper page
  39. McAndrew, 2017, A proof-of-concept investigation into ketamine as a pharmacological treatment for alcohol dependence: Study protocol for a randomised controlled trial, Trials, 18, 159, 10.1186/s13063-017-1895-6 · DOI · Paper page
  40. Rotge, 2010, The glutamate-based genetic immune hypothesis in obsessive-compulsive disorder. An integrative approach from genes to symptoms, Neuroscience, 165, 408, 10.1016/j.neuroscience.2009.10.043 · DOI
  41. Gipson, 2014, Rapid, transient synaptic plasticity in addiction, Neuropharmacology, 76, 276, 10.1016/j.neuropharm.2013.04.032 · DOI · Paper page
  42. Meye, 2015, Cocaine-Evoked negative symptoms require AMPA receptor trafficking in the lateral habenula, Nat. Neurosci., 18, 376, 10.1038/nn.3923 · DOI · Paper page
  43. Krystal, 2003, Altered NMDA glutamate receptor antagonist response in recovering ethanol-dependent patients, Neuropsychopharmacology, 28, 2020, 10.1038/sj.npp.1300252 · DOI
  44. Jones, J.L., Mateus, C.F., Malcolm, R.J., Brady, K.T., and Back, S.E. (2018). Efficacy of Ketamine in the Treatment of Substance Use Disorders: A Systematic Review. Front. Psychiatry, 9. · DOI · Paper page
  45. Li, 2019, Generality and opponency of rostromedial tegmental (RMTg) roles in valence processing, eLife, 8, e41542, 10.7554/eLife.41542 · DOI
  46. Li, 2019, Three Rostromedial Tegmental Afferents Drive Triply Dissociable Aspects of Punishment Learning and Aversive Valence Encoding, Neuron, 104, 987, 10.1016/j.neuron.2019.08.040 · DOI · Paper page
  47. Williams, 2019, Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism, Mol. Psychiatry, 24, 1779, 10.1038/s41380-019-0503-4 · DOI · Paper page
  48. Nakazato, 2010, Serum glutamine, set-shifting ability and anorexia nervosa, Ann. Gen. Psychiatry, 9, 29, 10.1186/1744-859X-9-29 · DOI · Paper page
  49. Levinson, 2016, Clarifying the prospective relationships between social anxiety and eating disorder symptoms and underlying vulnerabilities, Appetite, 107, 38, 10.1016/j.appet.2016.07.024 · DOI · Paper page
  50. Lechin, 2011, Anorexia nervosa versus hyperinsulinism: Therapeutic effects of neuropharmacological manipulation, Clin. Risk Manag., 7, 53
  51. Aoki, 2017, Synaptic changes in the hippocampus of adolescent female rodents associated with resilience to anxiety and suppression of food restriction-evoked hyperactivity in an animal model for anorexia nervosa, Brain Res., 1654, 102, 10.1016/j.brainres.2016.01.019 · DOI
  52. Chen, 2018, Single injection of ketamine during mid-adolescence promotes long-lasting resilience to activity-based anorexia of female mice by increasing food intake and attenuating hyperactivity as well as anxiety-like behavior, Int. J. Eat. Disord., 51, 1020, 10.1002/eat.22937 · DOI
  53. Hermens, 2020, Anorexia nervosa, zinc deficiency and the glutamate system: The ketamine option, Prog. Neuro Psychopharmacol. Biol. Psychiatry, 101, 109921, 10.1016/j.pnpbp.2020.109921 · DOI
  54. Campbell, 2018, New steps for treating alcohol use disorder, Psychopharmacology, 235, 1759, 10.1007/s00213-018-4887-7 · DOI
  55. Davis, 2017, Pharmacotherapy of eating disorders, Curr. Opin. Psychiatry, 30, 452, 10.1097/YCO.0000000000000358 · DOI · Paper page
  56. Martinotti, 2010, Pregabalin versus naltrexone in alcohol dependence: A randomised, double-blind, comparison trial, J. Psychopharmacol., 24, 1367, 10.1177/0269881109102623 · DOI · Paper page
  57. Martinotti, 2007, Efficacy and safety of aripiprazole in alcohol dependence, Am. J. Drug Alcohol Abus., 33, 393, 10.1080/00952990701313660 · DOI
  58. Breeksema, 2020, Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies, CNS Drugs, 34, 925, 10.1007/s40263-020-00748-y · DOI · Paper page
  59. Shulgin, 1979, Profiles of psychedelic drugs, J. Psychedelic Drugs, 11, 355, 10.1080/02791072.1979.10471421 · doi:10.1080/02791072.1979.10471421
  60. Thompson, 2020, Ketamine induces immediate and delayed alterations of OCD-like behavior, Psychopharmacology, 237, 627, 10.1007/s00213-019-05397-8 · DOI
  61. American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders (DSM–5), American Psychiatric Association. [5th ed.]. · DOI · Paper page
  62. McNaughton, 2020, Ketamine and neuroticism: A double-hit hypothesis of internalizing disorders, Personal. Neurosci., 3, e2, 10.1017/pen.2020.2 · DOI
  63. Kokane, 2020, Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant, Behav. Brain Res., 384, 112548, 10.1016/j.bbr.2020.112548 · DOI · Paper page

Cited by

See all 111

Metadata

Authors
Martinotti, G., Chiappini, S., Pettorruso, M., Mosca, A., Miuli, A., Di Carlo, F., D’Andrea, G., Collevecchio, R., Di Muzio, I., Sensi, S. L., & Di Giannantonio, M.
Venue
Brain Sciences
Publisher
MDPI AG
Published
2021-06-27
Volume
11
Issue
7
Pages
856
ISSN
2076-3425 (ISSN-L)
OpenAlex
W3175732576
Cited by
111
References
33
FWCI
9.47
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Therapeutic Potentials of Ketamine and Esketamine in Obsessive–Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature. https://app.cochat.ai/papers/10.3390/brainsci11070856
The paper
Martinotti, G., Chiappini, S., Pettorruso, M., Mosca, A., Miuli, A., Di Carlo, F., D’Andrea, G., Collevecchio, R., Di Muzio, I., Sensi, S. L., & Di Giannantonio, M. (2021). Therapeutic Potentials of Ketamine and Esketamine in Obsessive–Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature. Brain Sciences. https://doi.org/10.3390/brainsci11070856

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.